Balmforth A J, Parkinson F E, Altiok N, Fredholm B B
Department of Cardiovascular Studies, University of Leeds, England.
Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):303-10. doi: 10.1007/BF00173543.
We have examined the activation of a phospholipase C signal transduction pathway by a B2-bradykinin receptor in the human astrocytoma cell line D384 and how this influences D1-dopamine receptor stimulated cyclic AMP accumulation. Addition of bradykinin to D384 cells resulted in a concentration-dependent (10(-11)-10(-6) M) increase in the accumulation of [3H]inositol phosphates and a similar concentration-dependent transient increase in specific [3H]beta-phorbol-12,13-dibutyrate binding which is indicative of translocation of protein kinase C from the cytosol to the membrane. Changes in intracellular Ca2+ of single cells, measured using the fluorescent indicator dye fura-2, indicated that bradykinin produced a rapid, but transient, increase in intracellular calcium. The Ca2+ response was largely independent of extracellular Ca2+ supporting the idea that receptor activation leads to mobilization of Ca2+ from intracellular stores. However, extracellular Ca2+ was required for a response to a rechallenge with bradykinin. The bradykinin B2-receptor agonist kallidin increased cytosolic Ca2+ in a similar manner to bradykinin. The Ca2+ response to bradykinin could be partially reduced in the presence of the B2-receptor antagonist [D-Arg0-Hyp,D-Phe7,beta-(2-Thienyl)-Ala5,8]-bradykinin, whereas the B1-receptor agonists (Des-Arg9]-bradykinin and [Des-Arg10]-kallidin were ineffective. Bradykinin was also found to attenuate dopamine stimulated cyclic AMP accumulation in D384 cells, at similar concentrations previously observed to stimulate the phospholipase C signal transduction pathway, in the presence of the phosphodiesterase inhibitor, rolipram. In contrast, no attenuation was observed in the presence of the phosphodiesterase inhibitor 1-isobutyl 3-methylxanthine, although the level of dopamine stimulated cyclic AMP observed was lower than in the presence of rolipram.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了人星形细胞瘤细胞系D384中B2 -缓激肽受体对磷脂酶C信号转导途径的激活作用,以及这如何影响D1 -多巴胺受体刺激的环磷酸腺苷(cAMP)积累。向D384细胞中添加缓激肽导致[3H]肌醇磷酸积累呈浓度依赖性(10(-11)-10(-6) M)增加,并且特异性[3H]β -佛波醇 - 12,13 -二丁酸酯结合也有类似的浓度依赖性瞬时增加,这表明蛋白激酶C从胞质溶胶转位到细胞膜。使用荧光指示剂染料fura - 2测量单细胞内Ca2+的变化,表明缓激肽使细胞内钙迅速但短暂地增加。Ca2+反应在很大程度上不依赖于细胞外Ca2+,支持受体激活导致细胞内储存的Ca2+动员的观点。然而,再次用缓激肽刺激时需要细胞外Ca2+才能产生反应。缓激肽B2 -受体激动剂胰激肽以与缓激肽相似的方式增加胞质Ca2+。在存在B2 -受体拮抗剂[D - Arg0 - Hyp,D - Phe7,β-(2 -噻吩基)-Ala5,8]-缓激肽的情况下,对缓激肽的Ca2+反应可部分降低,而B1 -受体激动剂(去 - Arg9]-缓激肽和[去 - Arg10]-胰激肽无效。在磷酸二酯酶抑制剂咯利普兰存在的情况下,还发现缓激肽在先前观察到刺激磷脂酶C信号转导途径的类似浓度下减弱多巴胺刺激的D384细胞中环磷酸腺苷积累。相比之下,在磷酸二酯酶抑制剂1 -异丁基 - 3 -甲基黄嘌呤存在的情况下未观察到减弱,尽管观察到的多巴胺刺激的环磷酸腺苷水平低于咯利普兰存在时的水平。(摘要截短于250字)